ABCM: Abcam plc - Summary | Jitta

Abcam plc

NASDAQ:ABCM

Notice
Stock data is unavailable or the company’s delisted.
Price
$23.99
Loss Chance
47.5%
5.52JITTA SCORE
234.03%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (74)
Recent Business Performance (85)
Financial Strength (80)
Return to Shareholders (28)
Competitive Advantage (54)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Debt LevelLow Long Term Debt
Recent IPOLess than 3 years
Revenue and EarningEarning decline from 2019-2022
Operating MarginInconsistent
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.52
234.03%
2.22
139.24%
3.06
206.98%
Biotechnology
0.97
100.00%
0.97
100.00%
0.97
100.00%
COMPANY DESCRIPTION
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company’s principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.